5 AstraZeneca, AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity, Press Release, November 9, 2023
The SELECT trial enrolled over 17,000 patients with established cardiovascular disease and demonstrated a 20% reduction in major adverse cardiovascular events
This approach creates extreme caloric deficits of 1000+ calories per day, which the body compensates for by breaking down muscle at accelerated rates
Low concentrations of glutathione have been noted in individuals with asthma, viral infections, psoriasis, disease of the eye, Parkinsons disease and Multiple Sclerosis
Metformin activates AMPK/SIRT1/NF-B pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis
doi:10.1016/j.ntt.2006.05.003 Islam Z, Amuzie CJ, Harkema JR, Pestka JJ